Overview Financials News + Filings
|
|
Soul Biotechnology Corp
|
|
| Common Size Income Statement |
|
|
|
|
Annual | Quarterly | TTM |
|
| In millions, except per share items | Jun-30-23 | Mar-31-23 | Jun-30-22 | Mar-31-22 | Dec-31-21 | Sep-30-21 | Jun-30-21 | Mar-31-21 |
| | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q |
| Revenues | | | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Cost of goods sold | | | 39.1% | 41.0% | 99.8% | 99.6% | 99.5% | 99.2% |
| Gross profit | | | 60.9% | 59.0% | 0.2% | 0.4% | 0.5% | 0.8% |
| General and administrative | | | 241.4% | 128.2% | 137.3% | 163.1% | 195.8% | 253.4% |
| EBITDA | | | -161.6% | -60.1% | -137.1% | -162.7% | -195.3% | -252.6% |
| Depreciation | | | 18.9% | 9.1% | | | | |
| EBITA | | | -180.5% | -69.2% | -137.1% | -162.7% | -195.3% | -252.6% |
| Amortization of intangibles | | | 18.9% | 9.1% | | | | |
| EBIT | | | -199.5% | -78.3% | -137.1% | -162.7% | -195.3% | -252.6% |
| Pre-tax income | | | -200.3% | -78.3% | -137.0% | -195.0% | -260.1% | -356.3% |
| Income taxes | | | 6.5% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | | | -206.8% | -78.3% | -137.0% | -195.0% | -260.1% | -356.3% |
|